Nasr Aya Mohamed, Saad Mohab Alsaid, Mohamed Amer Salah, Hanafi Yousif Ahmad, Bazbaz Bilal Walid, Mohamed Sarra Salah Amer, Selim Sayed Mahmoud, Altawallbeh Zaid Fatehi
Alexandria University Main Hospital, Alexandria, Egypt.
Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt.
J Sex Med. 2025 Aug 4;22(8):1409-1421. doi: 10.1093/jsxmed/qdaf153.
Genitourinary syndrome of menopause (GSM) is characterized by vaginal dryness, itching, burning, pain during intercourse, and urinary symptoms. Traditionally, hormone replacement therapy (HRT), specifically estrogen therapy, has been the first-line treatment for GSM, due to its side effects, fractional CO2 laser therapy has emerged as an alternative for managing GSM symptoms.
The primary focus is to compare CO2 fractional laser therapy and estrogen therapy on postmenopausal women with GSM through systemically reviewing all the randomized controlled trials.Methods: A comprehensive search of electronic databases, including PubMed, Scopus, Web of Science, Medline, Cochrane, Scielo, UC Berkeley library, and Google Scholar, was performed in October 2024. The inclusion criteria targeted randomized controlled trials comparing CO2 fractional laser therapy and estrogen therapy on postmenopausal women with GSM, which used at least 1 of these outcomes: Female Sexual Function Index (FSFI), Vaginal Health Index, Visual Analog Score, and Urinary Distress Inventory 6.
Out of 688 studies, 7 studies were included for final analysis with a total of 302 participants: 154 had CO2 fractional laser therapy with a mean age of 55.9 years, and 148 had estrogen therapy with a mean age of 57.2 years. The analysis revealed no statistically significant difference between CO2 laser and estrogen in Vaginal Health Index (mean difference [MD], 1.60; 95% CI, -0.36 to 3.56; P = .09), FSFI-total (MD, 0.10; 95% CI, -2.03 to 2.23; P = .93), and Urinary Distress Inventory 6 (MD, -3.18; 95% CI, -6.77 to 0.42; P = .08). We used a sensitivity analysis on the FSFI-arousal subscale due to high heterogeneity, excluding 1 study. It showed that the CO2 laser group had a statistically significant difference when compared with the estrogen group (MD, 0.47; 95% CI, 0.15-0.79; P = .01).
CO2 laser therapy is an effective line of treatment for GSM. However, its comparison with estrogen therapy did not reach a statistically significant difference favoring one line over the other.
更年期泌尿生殖综合征(GSM)的特征为阴道干燥、瘙痒、烧灼感、性交疼痛及泌尿系统症状。传统上,激素替代疗法(HRT),尤其是雌激素疗法,一直是GSM的一线治疗方法,但由于其副作用,分次二氧化碳激光疗法已成为管理GSM症状的一种替代方法。
主要重点是通过系统回顾所有随机对照试验,比较二氧化碳分次激光疗法和雌激素疗法对患有GSM的绝经后女性的疗效。
2024年10月对电子数据库进行了全面检索,包括PubMed、Scopus、Web of Science、Medline、Cochrane、Scielo、加州大学伯克利分校图书馆和谷歌学术。纳入标准针对比较二氧化碳分次激光疗法和雌激素疗法对患有GSM的绝经后女性的随机对照试验,这些试验至少使用以下一项指标:女性性功能指数(FSFI)、阴道健康指数、视觉模拟评分和泌尿困扰量表6。
在688项研究中,7项研究纳入最终分析,共有302名参与者:154名接受二氧化碳分次激光疗法,平均年龄55.9岁;148名接受雌激素疗法,平均年龄57.2岁。分析显示,在阴道健康指数(平均差值[MD],1.60;95%置信区间,-0.36至3.56;P = 0.09)、FSFI总分(MD,0.10;95%置信区间,-2.03至2.23;P = 0.93)和泌尿困扰量表6(MD,-3.18;95%置信区间,-6.77至0.42;P = 0.08)方面,二氧化碳激光疗法和雌激素疗法之间无统计学显著差异。由于异质性高,我们对FSFI唤起子量表进行了敏感性分析,排除了1项研究。结果显示,与雌激素组相比,二氧化碳激光组有统计学显著差异(MD,0.47;95%置信区间,0.15 - 0.79;P = 0.01)。
二氧化碳激光疗法是治疗GSM的一种有效治疗方法。然而,它与雌激素疗法的比较未达到统计学显著差异,无法表明哪种疗法更具优势。